The Cancer Letter

Inside information on cancer research and drug development

Vol.
35
No.
12
December 28, 2012Dec 28, 2012
Free
DOWNLOAD THE PDF

Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

Two Regorafenib Trials Demonstrate Efficacy, Improve Overall and Progression-Free Survival

Volasertib Shows Response In 31 Percent of Acute Myeloid Leukemia Patients

Breast Cancer Risk Increases With Repeated CT Imaging

Scatter Radiation from Mammography Presents No Increased Cancer Risk

MRI, 3D Ultrasound Combination Can Guide Prostate Biopsies

Perifosine, Sorafenib Combination Well Tolerated in Several Lymphomas

NCI-Approved CTEP Trials For the Month of December

FDA Approves 35 Medicines In Fiscal 2012, Eight in Cancer

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account